This month COLOSSUS ( features their partners at HalioDx.

HalioDx ( is the pioneer of immuno-oncology diagnostic, a transforming approach of cancer care that benefits from novel and deep understanding of the tumour immune microenvironment. The company provides a unique and extensive range of proprietary assays that allow it to extract from the immune contexture of cancer patients the useful information to guide individual treatment strategy and drive the development of new therapies, notably immunotherapies.

HalioDx’s Immunoscore®  platform aims to improve day-to-day care for patients by providing routine and exploratory diagnostic solutions to clinicians, industrials and academic researchers. The company is based in France in Marseille and in Richmond, Virginia in the US.

Above: The COLOSSUS consortium at their Marseille plenary meeting hosted by HalioDx, October 2019

A version of this story appeared in the COLOSSUS 2020 newsletter, read it here.

Read a peer-reviewed publication with an independent review of the HalioDx Immunoscore here. Visit the HalioDx YouTube channel.

Learn more at the COLOSSUS website at View the COLOSSUS explainer video here. Follow the project on Twitter @COLOSSUSEU.

  COLOSSUS has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement no 754923. The material presented and views expressed here are the responsibility of the author(s) only. The EU Commission takes no responsibility for any use made of the information set out.